Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 GlobeNewswire - Thu Mar 19, 3:05PM CDT

CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.3600 (-2.86%)
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference GlobeNewswire - Tue Mar 3, 7:00AM CST

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.3600 (-2.86%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Mar 2, 3:05PM CST

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.3600 (-2.86%)
Akebia Therapeutics: Q4 Earnings Snapshot AP - Thu Feb 26, 6:30AM CST

Akebia Therapeutics: Q4 Earnings Snapshot

AKBA : 1.3600 (-2.86%)
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights GlobeNewswire - Thu Feb 26, 6:00AM CST

Q4 2025 net product revenues of  $54.3 million ; 2025 full-year net product revenues of $227.3 million , representing a 49% increase over 2024 full-year net product revenues Expect significant...

AKBA : 1.3600 (-2.86%)
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights GlobeNewswire - Thu Feb 19, 7:00AM CST

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December...

AKBA : 1.3600 (-2.86%)
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 GlobeNewswire - Wed Feb 4, 7:00AM CST

CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.3600 (-2.86%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Feb 2, 3:05PM CST

CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 1.3600 (-2.86%)
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook GlobeNewswire - Mon Jan 12, 7:00AM CST

 Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2 clinical trial studying focal segmental...

AKBA : 1.3600 (-2.86%)
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) GlobeNewswire - Tue Jan 6, 7:00AM CST

CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 1.3600 (-2.86%)

Barchart Exclusives

Silver Prices Have Plunged 20% in Just 1 Month. Should You Buy the Dip? Barchart - Tue Mar 24, 4:21PM CDT
Silver prices have slipped significantly in March, but there are ample reasons for long-term investors to load up on the white metal at the current price. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.